Gilead Sciences announced that the European Commission has approved Trodelvy as a first-line monotherapy for adults with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitors, based on the landmark Phase 3 ASCENT-03 study.
Gilead Sciences has commended the leadership of the South African Government and the Global Fund for accelerating early access to its long-acting HIV prevention medication, lenacapavir.
Trodelvy mTNBC (sacituzumab govitecan-hziy) has reached a pivotal regulatory milestone in the European Union. On May 22, 2026, Gilead Sciences announced that the Committee for [Read More…]
Gilead Sciences reports a strong Q1 2026 with $6.96 billion in revenue, driven by its industry-leading HIV portfolio and the rapid uptake of Yeztugo, despite acquisition-related guidance adjustments.
Gilead Sciences has finalized its $7.8 billion acquisition of Arcellx, Inc., positioning the company for the potential 2026 commercial launch of the BCMA-directed CAR T-cell therapy, anito-cel.
Gilead Sciences has entered into a definitive agreement to acquire Tubulis for up to $5 billion, adding the “best-in-class” TUB-040 asset and a next-generation ADC platform to its growing oncology portfolio.
Gilead has announced positive Phase 3 results for its investigational single-tablet regimen (STR) of bictegravir and lenacapavir (BIC/LEN) in the ARTISTRY-2 trial. The new combination met its primary endpoint, demonstrating non-inferiority to BIKTARVY in maintaining viral suppression in adults with HIV-1. This novel two-drug regimen combines the potent integrase inhibitor bictegravir with the first-in-class capsid inhibitor lenacapavir, representing a potential new, simplified treatment option for long-term HIV management.
Gilead Sciences announced its Phase 3 ASCENT-07 trial for Trodelvy® in first-line HR+/HER2-negative metastatic breast cancer did not meet its primary endpoint of progression-free survival (PFS). However, the company reported an “early trend” favoring Trodelvy for the key secondary endpoint of overall survival (OS), and the study will continue to gather more data on this measure.
Gilead Sciences (GILD) reported strong Q3 2025 financial results, with total revenues of $7.8 billion and non-GAAP diluted EPS jumping 22% to $2.47. The performance was driven by a 4% rise in its core business (excluding Veklury), led by its HIV franchise and $3.7 billion in Biktarvy sales. Despite a decline in Veklury and Cell Therapy revenue, the company raised its full-year 2025 diluted EPS guidance.
At The Liver Meeting® 2025, Gilead Sciences, Inc. will discuss new findings on liver diseases, such as viral hepatitis and Primary Biliary Cholangitis (PBC). Focus [Read More…]
